Hostname: page-component-cd9895bd7-gvvz8 Total loading time: 0 Render date: 2024-12-25T05:45:45.492Z Has data issue: false hasContentIssue false
  • English
  • Français

Assessment of Drugs in Sweden

Published online by Cambridge University Press:  10 March 2009

Barbro Westerholm
Barbro Westerholm
Affiliation:
National Corporation of Pharmacies, Sweden
Get access Rights & Permissions [Opens in a new window]

Extract

The assessment of drugs in Sweden has a long tradition that goes back to the seventeenth century when the Collegium Medicorum was established in 1663. One of its duties was to control the production of drugs in pharmacies. In 1688, Sweden got its first pharmacopoeia. In 1917, the Pharmaceutical Laboratory was founded as an advisory body of the National Board of Health and Welfare. The laboratory, now called the Department of Drugs, became responsible for evaluating drug applications, including information on their pharmaceutical and chemical properties, pharmacological actions, and clinical effects.

Type
Special Section: The Evaluation of Drugs: An International Perspective
Information
International Journal of Technology Assessment in Health Care , Volume 2 , Issue 4 , October 1986 , pp. 673 - 681
Copyright
Copyright © Cambridge University Press 1986

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

REFERENCES

1.Agenäs, I., & Jacobsson, M.Hur representativa är uppgifterna i diagnos-receptun-dersökningen? Svensk Farmaceutisk Tidskrift, 1980, 84, 324–25.Google Scholar
2.Boethius, G.Recording of drug prescriptions in the county of Jämtland, Sweden. Pattern of drug usage in 16,000 individuals 1970–1975. Acta Medica Scandinavica, 1977, 202, 241–45.Google Scholar
3.Böttiger, L. E., & Westerholm, B.Drug-induced blood dyscrasias in Sweden. British Medical Journal, 1973, 3, 339–43.CrossRefGoogle ScholarPubMed
4.Böttiger, L. E., & Westerholm, B.Oral contraceptives and thromboembolic disease. Acta Medica Scandinavica, 1971, 190, 455–63.CrossRefGoogle ScholarPubMed
5.Böttiger, L. E., Westerholm, B., & Strandberg, K.Drug-induced febrile mucocutaneous syndrome. Acta Medica Scandinavica, 1975, 118, 229–33.CrossRefGoogle Scholar
6.Ericsson, A., Källén, B., & Winberg, J.Surveillance of malformations at births: a comparison of two record systems run in parallel. International Journal of Epidemiology, 1977, 6, 35–41.CrossRefGoogle Scholar
7.Fagius, J., Osterman, P-O., Sidén, Å., & Wiholm, B-E.Guillain-Barré syndrome following zimeldine treatment. Journal of Neurology, Neurosurgery and Psychiatry, 1985, 48, 65–69.CrossRefGoogle ScholarPubMed
8.Jacobsson, M., & Kristoferson, K.Metodiken vid diagnos-receptundersökningen. Svensk Farmaceutisk Tidskrift, 1980, 84, 321–23.Google Scholar
9.Jönsson, B. A review of the macroeconomic evaluation of cimetidine. In Culyer, A. J. and Horrisberger, B. (eds.), Economic and Medical Evaluation of Health Care Technologies. Berlin: Springer Verlag, 1983, 250–61.Google Scholar
10.Persson, I., Adami, H. O., Lindberg, B. S., Johansson, E. D. B., & Manell, P.Characteristics of estrogen-treated women. Acta Obstetrica Gynecologica Scandinavica, 1983, 62, 297–302.CrossRefGoogle ScholarPubMed
11.Westerholm, B.Drug utilization studies—a valuable tool for the optimization of drug therapy and drug control. Journal of Social and Administrative Pharmacy, 1983, 1, 1–8.Google Scholar